Arena Pharmaceuticals (ARNA) Research Coverage Started at Credit Suisse Group

Credit Suisse Group initiated coverage on shares of Arena Pharmaceuticals (NASDAQ:ARNA) in a report issued on Wednesday, MarketBeat.com reports. The firm issued an outperform rating and a $44.00 target price on the biopharmaceutical company’s stock.

Several other research firms have also issued reports on ARNA. Zacks Investment Research lowered shares of Arena Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, January 10th. Wells Fargo & Co upgraded shares of Arena Pharmaceuticals from a market perform rating to an outperform rating in a research report on Wednesday, January 3rd. Leerink Swann restated a positive rating and issued a $56.00 price target (up previously from $53.00) on shares of Arena Pharmaceuticals in a research report on Wednesday. Cantor Fitzgerald restated a buy rating and issued a $45.00 price target on shares of Arena Pharmaceuticals in a research report on Wednesday. Finally, BidaskClub lowered shares of Arena Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $38.38.

Arena Pharmaceuticals (NASDAQ ARNA) traded up $1.48 during trading on Wednesday, reaching $35.60. 614,725 shares of the company’s stock traded hands, compared to its average volume of 573,423. The company has a debt-to-equity ratio of 0.27, a quick ratio of 4.32 and a current ratio of 4.42. The firm has a market capitalization of $1,397.76, a price-to-earnings ratio of -38.28 and a beta of 1.50. Arena Pharmaceuticals has a 12-month low of $11.30 and a 12-month high of $41.92.

Arena Pharmaceuticals (NASDAQ:ARNA) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.01. The firm had revenue of $7.95 million for the quarter, compared to analyst estimates of $5.48 million. Arena Pharmaceuticals had a negative net margin of 36.78% and a negative return on equity of 34.12%. The firm’s quarterly revenue was down 58.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.05) earnings per share. analysts predict that Arena Pharmaceuticals will post -3.13 EPS for the current fiscal year.

A number of institutional investors have recently bought and sold shares of the stock. Balyasny Asset Management LLC acquired a new position in Arena Pharmaceuticals in the 2nd quarter worth approximately $12,183,000. Pictet Asset Management Ltd. acquired a new position in Arena Pharmaceuticals in the 3rd quarter worth approximately $13,656,000. Point72 Asset Management L.P. acquired a new position in Arena Pharmaceuticals in the 3rd quarter worth approximately $9,973,000. JPMorgan Chase & Co. boosted its stake in Arena Pharmaceuticals by 16,992.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 317,754 shares of the biopharmaceutical company’s stock worth $5,361,000 after purchasing an additional 315,895 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its stake in Arena Pharmaceuticals by 16.6% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 209,085 shares of the biopharmaceutical company’s stock worth $7,103,000 after purchasing an additional 29,732 shares during the period. 72.82% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Arena Pharmaceuticals (ARNA) Research Coverage Started at Credit Suisse Group” was first posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The legal version of this piece of content can be accessed at https://baseballnewssource.com/markets/arena-pharmaceuticals-arna-research-coverage-started-at-credit-suisse-group/1850062.html.

Arena Pharmaceuticals Company Profile

Arena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing small molecule drugs across a range of therapeutic areas. The Company has three primary investigational clinical programs: etrasimod (APD334) in Phase II evaluation for ulcerative colitis, APD371 entering Phase II evaluation for the treatment of pain associated with Crohn’s disease, and ralinepag (APD811) in Phase II evaluation for pulmonary arterial hypertension (PAH).

Analyst Recommendations for Arena Pharmaceuticals (NASDAQ:ARNA)

Receive News & Ratings for Arena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Giants Will Retire No. 25 of Barry Bonds in August
Giants Will Retire No. 25 of Barry Bonds in August
Mookie Betts Awarded Arbitration of $10.5 Million
Mookie Betts Awarded Arbitration of $10.5 Million


Leave a Reply

 
© 2006-2018 BBNS.